Breast Cancer Diagnostics Market – By Product (Instruments, Kits & Consumables), Test Type (Imaging, Biopsy, Genomic Test, Blood Test), Cancer Type (Ductal Carcinoma in Situ, Invasive Ductal Carcinoma), Application, End-use - Global Forecast 2024 – 2032

Breast Cancer Diagnostics Market Size

Breast Cancer Diagnostics Market size was valued at approximately USD 28.2 billion in 2023 and is projected to grow at a CAGR of 10.2% from 2024 to 2032. Breast cancer diagnostics encompass various tests and procedures used to detect and diagnose breast cancer. These diagnostics are essential for early detection, accurate diagnosis, and effective treatment planning.
 

Breast cancer remains one of the most prevalent forms of cancer worldwide, with incidence rates steadily increasing. The American Cancer Society estimates that in 2024, around 310,720 new cases of invasive breast cancer will be diagnosed in women in the U.S. Additionally, approximately 56,500 new cases of ductal carcinoma in situ (DCIS) are expected, and about 42,250 women will die from breast cancer. This growing prevalence is primarily due to aging populations, lifestyle changes, and improved screening and detection methods. Consequently, as more women are diagnosed with breast cancer, the demand for effective cancer diagnostics, estimated to reach USD 324 billion by 2032, has surged.
 

Governments and health organizations worldwide increasingly recognize the importance of early detection and treatment of breast cancer. Numerous initiatives and awareness programs have been launched to educate the public about breast cancer and the importance of regular screenings. Campaigns such as Breast Cancer Awareness Month, free or subsidized mammography programs, and widespread public health campaigns aim to increase participation in breast cancer screening. These efforts are crucial for promoting early diagnosis, which is vital for improving survival rates. Additionally, government support and funding for research and development in breast cancer diagnostics further bolster the market.
 

Breast Cancer Diagnostics Market Trends

• Technological advancements in breast cancer diagnostics have transformed the detection and management of the disease. Innovations such as digital mammography, 3D mammography (tomosynthesis), MRI systems, ultrasound, and molecular diagnostics have significantly improved the accuracy and efficiency of breast cancer detection. These advanced diagnostic tools enable earlier and more precise identification of breast cancer, often at stages when the disease is most treatable.
   
• Additionally, the integration of artificial intelligence (AI) and machine learning algorithms into diagnostic and medical imaging has enhanced the interpretation of results, reducing false positives and negatives. These technological advancements not only improve patient outcomes but also drive the demand for cutting-edge diagnostic equipment and services, contributing to the growth of the market
  .

Breast Cancer Diagnostics Market Analysis

Based on product, the market is divided into instruments, and kits and consumables. The instruments segment of the market is forecasted to reach USD 40.4 billion by 2032.
 

• Advancements in diagnostic technologies, such as mammography systems, MRI, and ultrasound, have significantly improved the accuracy and efficiency of breast cancer detection, stimulating increased adoption.
   
• Additionally, the rising incidence of breast cancer worldwide necessitates early and precise diagnosis, further boosting the demand for advanced diagnostic instruments.
   
• Government initiatives and public awareness campaigns promoting regular screenings also contribute to the market growth. Moreover, ongoing research and development efforts are leading to the introduction of innovative diagnostic tools, which are expected to enhance the overall market expansion.
   

Based on test type, the breast cancer diagnostics market is bifurcated into imaging, biopsy, genomic tests, blood tests, and other test types. The imaging segment is further divided into mammography, MRI, ultrasound, and PET/CT. The imaging segment accounted for USD 13.2 billion in 2023.
 

• This segment includes key modalities such as mammography, MRI, ultrasound, and PET/CT scans, each playing a crucial role in detecting and diagnosing breast cancer at various stages.
   
• Mammography remains a cornerstone due to its widespread adoption and effectiveness in screening for early signs of breast abnormalities.
   
• MRI and ultrasound offer complementary diagnostic insights, particularly for evaluating dense breast tissue and detecting tumors in younger women or those with dense breasts where mammography might be less effective.
   
• PET/CT scans provide valuable information on the metabolic activity of suspected tumors, aiding in staging and treatment planning.
   
• The robust growth of the imaging segment can be attributed to advancements in technology, increasing awareness, and proactive screening initiatives, all contributing to improved detection rates and patient outcomes in breast cancer diagnostics.
   

Based on cancer type, the breast cancer diagnostics market is bifurcated into ductal carcinoma in situ, invasive ductal carcinoma, inflammatory breast cancer, and metastatic breast cancer. The invasive ductal carcinoma segment accounted for USD 19.8 billion in 2023.
 

• Invasive ductal carcinoma (IDC), also referred to as infiltrating ductal carcinoma, is the most common type of breast cancer, accounting for about 75% of all cases according to the American Cancer Society. This high prevalence significantly drives the demand for diagnostic procedures and tools.
   
• Advances in diagnostic technologies, such as imaging techniques, biopsies, and molecular diagnostics, have enhanced the detection and characterization of IDC, contributing to market growth.
   
• Moreover, increased awareness and screening initiatives have led to earlier and more frequent diagnoses, further boosting the market.
   
• The combination of IDC's high prevalence, technological advancements, and proactive healthcare measures has established IDC as the dominant segment in the market.
   

Based on application, the breast cancer diagnostics market is segmented into screening, diagnostic and predictive, prognostic, and research. The diagnostic and predictive segment accounted for USD 13.5 billion in 2023.
 

• This segment's prominence can be attributed to its pivotal role in early detection and personalized treatment planning. Diagnostic tools such as mammography, MRI, and ultrasound enable accurate identification of breast abnormalities, aiding clinicians in making informed decisions regarding further diagnostic procedures or treatments.
   
• Moreover, predictive tests, including genetic screening for BRCA mutations, are increasingly adopted to assess an individual's risk of developing breast cancer, guiding proactive management strategies.
   
• Therefore, as advancements in technology and biomarker research continue to enhance the precision and efficacy of diagnostic and predictive tools, this segment is expected to remain a cornerstone of breast cancer care, accelerating continued market growth and improving patient outcomes globally.
   

Based on end-use, the breast cancer diagnostics market is bifurcated into hospitals and clinics, diagnostic centers, cancer research institutes, and other end-users. The hospitals and clinics segment accounted for USD 14.7 billion in 2023.
 

• Hospitals and clinics serve as primary points of contact for patients seeking comprehensive diagnostic services, including screening, imaging, biopsies, and consultations with specialized oncologists.
   
• Their pivotal role stems from their ability to offer integrated healthcare services under one roof, ensuring timely diagnosis and treatment initiation, which are critical in managing breast cancer effectively.
   
• Moreover, the presence of advanced diagnostic equipment and skilled healthcare professionals in hospitals and clinics enhances diagnostic accuracy and patient care outcomes.
   
• Thus, as hubs for both routine screenings and complex diagnostic procedures, hospitals and clinics continue to stimulate substantial revenue in the market, reflecting their central role in the healthcare ecosystem dedicated to combating breast cancer.
   

The growth of the breast cancer diagnostics market in the U.S., projected to reach USD 27.2 billion by 2032.
 

• The U.S. invests significantly in healthcare innovation and technology, fostering a robust market for advanced diagnostic tools. This includes ongoing advancements in imaging technologies such as digital mammography, breast MRI, and ultrasound, which improve early detection rates and diagnostic accuracy.
   

The breast cancer diagnostics market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• The increasing prevalence of breast cancer in the UK highlights the critical demand for efficient diagnostic solutions. According to Breast Cancer UK, approximately 56,000 new cases are diagnosed in women annually, translating to more than 150 cases each day. Additionally, around 400 new cases are reported annually in men. This cancer ranks as the most commonly diagnosed in the UK, representing 15% of all new cancer cases and 30% of new cancer cases among females. Therefore, as the prevalence rises, so does the imperative for effective diagnostics, propelling the market expansion.
   

Japan breast cancer diagnostics market is anticipated to witness lucrative growth between 2024 – 2032.
 

• Increased awareness about breast cancer screening among women and healthcare providers is promoting early detection and diagnosis. National and local screening programs play a crucial role in driving market growth by encouraging regular screenings and timely intervention.
   

The market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• Saudi Arabia has been increasing its healthcare expenditure, aiming to improve healthcare infrastructure and services. This includes investments in diagnostic technologies and facilities, which will support the growth of the market.
   

Breast Cancer Diagnostics Market Share

The market is highly competitive, with major global companies and smaller to medium-sized firms vying for market leadership. Continuous innovation is crucial, as companies frequently introduce new diagnostic products that utilize advanced technologies like AI-driven image analysis, liquid biopsy, and genomic profiling. Industry leaders maintain their competitive edge through significant investments in research and development, driving groundbreaking advancements in early detection and personalized treatment strategies. Strategic partnerships, acquisitions, and mergers are essential for consolidating market positions and expanding global footprints, allowing companies to address evolving healthcare needs and strengthen their competitive advantage in the dynamic breast cancer diagnostics landscape.
 

Breast Cancer Diagnostics Market Companies

Some of the eminent market participants operating in the breast cancer diagnostics industry include:

• Argon Medical Devices
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Canon Inc.
• Danaher Corporation
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd
• FUJIFILM Holdings Corporation
• Hologic, Inc.
• Illumina, Inc.
• Koninklijke Philips N.V.
• Myriad Genetics, Inc.
• QIAGEN N.V.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
   

Breast Cancer Diagnostics Industry News:

• In May 2023, Pfizer and Thermo Fisher Scientific Inc. partnered to expand NGS-based testing access in over 30 countries across Latin America, Africa, the Middle East, and Asia. This collaboration enhanced local healthcare by enabling quicker genetic analysis for personalized therapy selection in lung and breast cancer patients. The strategic collaboration expanded the companies' geographical footprint and customer base.
   
• In March 2022, Myriad Genetics, Inc., received approval from the U.S. Food and Drug Administration (FDA) for its BRACAnalysis CDx test as a companion diagnostic. This approval allowed the test to identify patients with germline BRCA-mutated (gRBCAm), HER2-negative, high-risk early-stage breast cancer, potentially benefiting from Lynparza (olaparib) and provided the company with a significant competitive advantage in the market.
   

The breast cancer diagnostics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Instruments
• Kits and consumables

Market, By Test Type

• Imaging
  • Mammography
  • MRI
  • Ultrasound
  • PET/CT
• Biopsy
• Genomic tests
• Blood tests
• Other test types

Market, By Cancer Type

• Ductal carcinoma in situ
• Invasive ductal carcinoma
• Inflammatory breast cancer
• Metastatic breast cancer

Market, By Application

• Screening
• Diagnostic and predictive
• Prognostic
• Research

Market, By End-use

• Hospitals and clinics
• Diagnostic centers
• Cancer research institutes
• Other end-users

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa